Monte Rosa Therapeutics (GLUE) Gains from Sales and Divestitures: 2023-2025
Historic Gains from Sales and Divestitures for Monte Rosa Therapeutics (GLUE) over the last 2 years, with Sep 2025 value amounting to $112,159.
- Monte Rosa Therapeutics' Gains from Sales and Divestitures fell 8.09% to $112,159 in Q3 2025 from the same period last year, while for Sep 2025 it was $112,159, marking a year-over-year decrease of 8.09%. This contributed to the annual value of $122,034 for FY2024, which is 19.81% up from last year.
- Latest data reveals that Monte Rosa Therapeutics reported Gains from Sales and Divestitures of $112,159 as of Q3 2025, which was down 0.00% from $112,159 recorded in Q2 2025.
- In the past 5 years, Monte Rosa Therapeutics' Gains from Sales and Divestitures ranged from a high of $122,034 in Q3 2024 and a low of $4,691 during Q1 2024.
- For the 3-year period, Monte Rosa Therapeutics' Gains from Sales and Divestitures averaged around $85,112, with its median value being $99,460 (2023).
- As far as peak fluctuations go, Monte Rosa Therapeutics' Gains from Sales and Divestitures plummeted by 85.87% in 2024, and later surged by 39.23% in 2025.
- Over the past 3 years, Monte Rosa Therapeutics' Gains from Sales and Divestitures (Quarterly) stood at $101,855 in 2023, then climbed by 19.81% to $122,034 in 2024, then declined by 8.09% to $112,159 in 2025.
- Its Gains from Sales and Divestitures stands at $112,159 for Q3 2025, versus $112,159 for Q2 2025 and $122,034 for Q4 2024.